1.1 Dapagliflozin is recommended, within its marketing authorisation, as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Why the committee made this recommendation
Current standard care for heart failure with preserved or mildly reduced ejection fraction is loop diuretics and treatment for other conditions the person may have. These manage symptoms, but do not reduce hospitalisations for heart failure.
Clinical trial evidence shows that dapagliflozin plus standard care reduces the combined risk of dying from cardiovascular causes or likelihood of first hospitalisation for heart failure compared with placebo plus standard care. Evidence suggests that dapagliflozin could reduce the chance of dying from cardiovascular or other causes.
The cost-effectiveness estimates are below what NICE considers an acceptable use of NHS resources. So, dapagliflozin is recommended.